A Phase 2 interventional study of dexmedetomidine transdermal systems in agitation associated with Alzheimer's dementia

Study Description

Evaluating the effectiveness of dexmedetomidine transdermal patches in reducing agitation in Alzheimer's patients

Study Details

Registry ID:

NCT06052254

Conditions:

Agitation

Phase:

Phase 2

Target Enrollment:

150 participants

Start Date:

September 16, 2025

Age Range:

0–999 years

Healthy Volunteers:

No

Study Locations (7 sites)

• Vitalix
  Worcester, MassachusettsUnited States, United States
• Global Medical Institutes Florida LLC
  Miami, FloridaUnited States, United States
• Miami Jewish Health
  Miami, FloridaUnited States, United States
• Personal Physician Care
  Delray Beach, FloridaUnited States, United States
• Arrow Clinical Trials
  Daytona Beach, FloridaUnited States, United States
• Professional Health Care of Pinellas, LLC
  St. Petersburg, FloridaUnited States, United States
• Inland Psychiatric Medical Group
  Chino, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →